Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.
TTFields Earns Japanese Approval in Unresectable Advanced/Recurrent NSCLC

September 15th 2025

The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.
Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

September 13th 2025

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.
Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

September 12th 2025

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.
SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

September 11th 2025

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC
Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

September 9th 2025

Video Series
Video Interviews
Podcasts
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.
Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.
Latest CME Events & Activities

More News